Brighter announces Actiste pricing.
Brighter's award-winning service for insulin-treated diabetics – Actiste® Diabetes Management as a Service – is initially introduced to the market in the GCC, Southeast Asia and the Nordics.
Actiste consists of a unique and patented device reducing the number of steps needed to manage diabetes by 67 percent, and a digital infrastructure for smart services, healthcare contact, subscriptions, data management and personal coaching stimulating behavioral change and increased adherence in treatments.
The service enables a higher degree of self-monitoring and increased automation in costly diabetes treatments. The Business Model and Multi-Sided Market Platform – The Benefit Loop® – is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their relatives and friends, caregivers, healthcare providers, research & development, the pharmaceutical industry, and society as a whole.
The market introduction is ongoing and the company’s estimates of segment size and ideal target markets were communicated earlier this year, in which the potential for the company's 14 initial target markets is estimated to over 30 million sold Actiste subscriptions until 2023.
Brighter has developed individual marketing strategies for the different regions. Some will be penetrated with partners, others with our own sales force, a few more through healthcare institutions and insurance companies. Similarly, the revenue- and sales model is partially influenced by regional market conditions.
Based on the prevailing market conditions and expected future market situation, Brighter has identified an average consumer price for Actiste of approximately EUR 60 per month, for the basic level subscription, including data sharing only with relatives and their close associates. For more extensive subscriptions, the price could range up to EUR 110 per month. The price is also affected to a certain extent by regional healthcare systems and societal conditions.
“In agreement with potential customers we have identified a sustainable pricing level, meaning we can maintain a long-term shareholder value while still being competitive today and in the future. The average price for the basic level subscription is approximately EUR 60 per month, and potentially up to EUR 110 per month depending on which additional services are selected,” says Truls Sjöstedt, Brighter’s CEO and founder.
“With Actiste, we are opening up a new, highly sought, market segment by filling the gap between traditional budget solutions, characterized by inefficiency, and the more expensive niche solutions that are suitable only for a minimal part of all insulin-treated diabetics," says Truls Sjöstedt.
For more information regarding Brighter's market, competition and unique advantages, please contact CEO Truls Sjöstedt or read the official comment, published June 27, 2018 (in Swedish only).
For more information, please contact:
Truls Sjöstedt, CEO
Telefon: +46 709 73 46 00
E-post: truls.sjostedt@brighter.se
Henrik Norström, COO
Telefon: +46 733 40 30 45
E-post: henrik.norstrom@brighter.se
About Actiste
Brighter's solution Actiste® handles most of the self-monitoring and treatment of insulin-treated diabetes in a single easy-to-use device. Measurement of glucose levels, insulin injections, automatic logging, and timing of all activities are performed from a single unit. Actiste is connected via an autonomous and secure mobile connection, and information can be automatically shared with selected recipients through The Benefit Loop®, Brighter's open cloud-based service where data is collected, processed and analyzed with patient consent.
Validated user-generated data, such as glucose levels or insulin doses, can be automatically transferred electronically to many different constituents. The patient selects when and how data is shared and who will have access to it. Through The Benefit Loop, different services can motivate patients with chronic illnesses to change their behavior, which can save lives, reduce relatives' concerns, and release enormous healthcare resources. www.actiste.com
About Brighter
Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare’s biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. www.brighter.se
The Company's shares are listed on NASDAQOMX First North/BRIG. Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 08:30 CEST on August 16, 2018.
